Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib et al. · New England Journal of Medicine · 2012 · 2K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

Claire Harrison, Jean‐Jacques Kiladjian, Haifa Kathrin Al‐Ali et al. · New England Journal of Medicine · 2012 · 1.8K citations · Full text

Medicine, Hematology, Pharmacology +10

Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

Alessandro M. Vannucchi, Jean‐Jacques Kiladjian, Martin Grießhammer et al. · New England Journal of Medicine · 2015 · 872 citations

Medicine, Hematology, Pharmacology +14

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

Tiziano Barbui, Giovanni Barosi, Gunnar Birgegård et al. · Journal of Clinical Oncology · 2011 · 834 citations · Full text

Medicine, Hematology, Oncology +17

Cardiovascular Events and Intensity of Treatment in Polycythemia Vera

Roberto Marchioli, Guido Finazzi, Giorgina Specchia et al. · New England Journal of Medicine · 2012 · 820 citations · Full text

Medicine, Hematology, Pharmacotherapy +10